IMMUNITYBIO, INC. (IBRX)

8.05 -4.17% (-0.35)

Over 1Y: +245.5%

2026-08-28
Style
Area Line Line with markers Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

5 10
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '23 — Revenue: 82K Q3 '23 — Operating Cash Flow: -87.4M Q3 '23 — Free Cash Flow: -93.1M Q3 '23 — Net Income: -95.6M Q4 '23 — Revenue: 139K Q4 '23 — Operating Cash Flow: -115.3M Q4 '23 — Free Cash Flow: -123.2M Q4 '23 — Net Income: -233.4M Q1 '24 — Revenue: 40K Q1 '24 — Operating Cash Flow: -107M Q1 '24 — Free Cash Flow: -108.2M Q1 '24 — Net Income: -134.1M Q2 '24 — Revenue: 1M Q2 '24 — Operating Cash Flow: -100.3M Q2 '24 — Free Cash Flow: -101.1M Q2 '24 — Net Income: -134.6M Q3 '24 — Revenue: 6.1M Q3 '24 — Operating Cash Flow: -98.8M Q3 '24 — Free Cash Flow: -101.6M Q3 '24 — Net Income: -85.7M Q4 '24 — Revenue: 7.6M Q4 '24 — Operating Cash Flow: -85.1M Q4 '24 — Free Cash Flow: -87.3M Q4 '24 — Net Income: -59.2M Q1 '25 — Revenue: 16.5M Q1 '25 — Operating Cash Flow: -85.9M Q1 '25 — Free Cash Flow: -87M Q1 '25 — Net Income: -129.6M Q2 '25 — Revenue: 26.4M Q2 '25 — Operating Cash Flow: -79.7M Q2 '25 — Free Cash Flow: -80.8M Q2 '25 — Net Income: -92.6M Q3 '25 — Revenue: 32.1M Q3 '25 — Operating Cash Flow: -68.9M Q3 '25 — Free Cash Flow: -69.6M Q3 '25 — Net Income: -67.3M Q4 '25 — Revenue: 38.3M Q4 '25 — Operating Cash Flow: -70.4M Q4 '25 — Free Cash Flow: -71.3M Q4 '25 — Net Income: -61.9M Q1 '26 — Revenue: 44.2M Q1 '26 — Operating Cash Flow: -75.4M Q1 '26 — Free Cash Flow: -77.1M Q1 '26 — Net Income: -632.8M Q2 '26 — Revenue: 51.2M Q2 '26 — Operating Cash Flow: -66.5M Q2 '26 — Free Cash Flow: -70M Q2 '26 — Net Income: -230.4M -600M -450M -300M -150M 0 150M
Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.1
SBC / sales 20.7%
OE margin -194.5%
Oper. margin -151.9%
Accruals -113.2%
Gross margin 99.3%
EBITDA margin -141.9%
FCF margin -173.8%
OCF margin -169.6%
Profit margin -598.6%
ROA -157.9%
ROCE -45.6%
OCF / EBIT —
ROE —
ROIC —

4 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

3.7
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.5
ND/EBITDA —
Cash / Debt 1407.0×
Debt payback 0.0 yr
Quick ratio 5.7×
Cash runway 1.2 yr
F-score 4.5 pts
Debt / Eq —
Equity / Assets —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales CAGR 4Y +231.9%
Sales/sh Y/Y +123.0%
Sales Q/Q +93.9%
Shares change +31.4%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.